Biohaven Financial Ratios
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.08+0.15 (+1.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biohaven ratio analysis
Return on equity reached -1418.8%, meaning Biohaven generated -14.19 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 4.59 versus 0.00 the year before, and the current ratio was 3.18. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Biohaven financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / book | 22.40 | 8.33 | 7.12 | 1.15 | — | — |
| Return on equity (ROE) | -1,418.8% | -199.9% | -95.4% | -105.8% | -616.3% | -707.2% |
| Return on assets (ROA) | -163.7% | -137.6% | -79.5% | -86.2% | -150.5% | — |
| Debt / equity | 4.59 | 0.00 | — | — | — | — |
| Current ratio | 3.18 | 3.49 | 7.98 | 6.52 | 2.26 | — |